病毒性肝炎患者血清胰岛素样生长因子结合蛋白3浓度的测定及对肝功能的评价

罗开忠; 苏先狮; 蒋永芳

病毒性肝炎患者血清胰岛素样生长因子结合蛋白3浓度的测定及对肝功能的评价

基金项目:

长沙市科技局课题资助(K041118-32)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1950
- HTML全文浏览量: 7
- PDF下载量: 740
- 被引次数: 0
出版历程
- 出版日期: 2006-01-20

Measurement of serum level of insulin-like growth factor binding protein-3 in patients with viral hepatitis and its assessment on liver function

Research funding:

摘要

摘要: 探讨各型病毒性肝炎患者血清胰岛素样生长因子结合蛋白-3（Insulin-like growth factor binding protein3,IGFBP-3）浓度的变化及其对肝功能的评价。经ELISA法检测,10例正常对照、10例急性肝炎、10例慢性肝炎中度、11例慢性肝炎重度、12例慢性重型肝炎及11例肝硬化患者血清中IGFBP-3的浓度分别为4891.63±1482.91、4243.88±1086.02、3361.38±584.11、3021.63±946.48、1951.13±791.96及1146.93±443.15ng/ml。除急性肝炎组外,肝炎患者血清IGFBP-3浓度均显著低于正常对照组;血清IGFBP-3浓度与血清白蛋白、前白蛋白呈正相关,而与凝血酶原时间、总胆红素及直接胆红素呈负相关,与AST、ALT无显著相关性。血清IGFBP-3浓度能较好地反映各型病毒性肝炎患者的肝功能损害程度。
- 病毒性肝炎 /
- 胰岛素样生长因子结合蛋白-3 /
- 肝功能
Abstract: To investigate its level in patients with different kinds of viral hepatitis and its assessment on liver function, the serum level of insulin-like growth factor binding protein-3 (IGFBP-3) was measured by ELISA in 10 healthy controls, 10 cases with acute hepatitis, 10 cases with moderate degree chronic hepatitis, 11 cases with severe degree chronic hepatitis, 12 cases of severe ( ) hepatitis and 11 cases of cirrhosis, whose results were 4891.63±1482.91、4243.88±1086.02、3361.38±584.11、3021.63±946.48、1951.13±791.96 and 1146.93±443.15 ng/ml, respectively.Compared with healthy controls, serum IGFBP-3 levels in patients with viral hepatitis were much lower except acute hepatitis.The serum IGFBP-3 level decreases as the damage of liver function aggravates.There was significant positive correlation between serum IGFBP-3 and serum albumin, prealbumin, while negative with serum prothrombin time, total serum bilirubin and direct serum bilirubin.No significant correlation was found between serum IGFBP-3 and ALT, AST.Serum IGFBP-3 level is a good marker for the evaluation of liver function.
- viral hepatitis /
- insulin-like growth factor binding protein-3 /
- liver function

HTML全文

参考文献(11)

[1]Monzavi R, Cohen P.IGFs and IGFBPs∶role in health and disease[J].Best Pract Res Clin Endocrinol Metab, 2002, 16 (3) ∶433-447.

[2]吴云林, 叶静, 张曙, 等.肝硬化患者血清胰岛素样生长因子及其结合蛋白测定与肝功能状况的关系[J].中华消化杂志, 2002, 22 (10) ∶601-604.

[3]Sidlova K, Pechova M, Akotaska K, et al.Insulin-like growth factorbinding protein-3 in patients with liver cirrhosis[J].Physiol Res, 2002, 51 (6) ∶587-90.

[4]Shaarawy M, Fikry MA, Massoud BA, et al.Insulin-like growth factorbinding protein-3∶a novel biomarker for the assessment of the syntheticcapacity of hepatocytes in liver cirrhosis[J].J Clin Endocrinol Metab, 1998, 83 (9) ∶3316-9.

[5] 中华医学会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) ∶324-329.

[6]Weber MM, Auernhammer CJ, Lee PD, et al.Insulin-like growth fac-tors and insulin-like growth factor binding proteins in adult patients withsevere liver disease before and after orthotopic liver transplantation[J].Horm Res, 2002, 57 (3-4) ∶105-12.

[7]Schalch DS, Kalayoglu M, Pirsch JD, et al.Serum insulin-like growthfactors and their binding proteins in patients with hepatic failure and afterliver transplantation[J].Metabolism, 1998, 47 (2) ∶200-6.

[8]Ottesen LH, Bendtsen F, Flyvbjerg A.The insulin-like growth factorbinding protein 3 ternary complex is reduced in cirrhosis[J].Liver, 2001, 21 (5) ∶350-6.

[9]Donaghy AJ, Delhanty PJ, Ho KK, et al.Regulation of the growth hor-mone receptor/binding protein, insulin-like growth factor ternary com-plex system in human cirrhosis[J].J Hepatol, 2002, 36 (6) ∶751-8.

[10]Wallace JD, Abbott-Johnson WJ, Crawford DH, et al.GH treatmentin adults with chronic liver disease:a randomized, double-blind, placebo-controlled, cross-over study[J].J Clin Endocrinol Metab, 2002, 87 (6) ∶2751-9.

[11]郭新会, 陈义森, 金荣华, 等.重组人生长激素治疗肝炎后肝硬化患者低蛋白血症的实验与临床研究[J].中华实验和临床毒学杂志, 2001.15 (4) ∶339-341.

施引文献

资源附件(0)

访问统计